Non-pCR for HER2+ breast cancer has been repeatedly identified as the most significant adverse prognostic factor for both DFS and OS and justified a global clinical trial in an attempt to improve outcomes for this high-risk, non-pCR, HER2+ patient population. This evidence concerns the gene ERBB2 and breast cancer.